

February 14, 2020

To,

BSE Limited.

Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

Scrip code: 540679

National Stock Exchange of India Limited

Listing Department, “Exchange Plaza”,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051

Scrip code: SMSLIFE

Through: BSE Listing Center

Through: NEAPS

Dear Sir/Madam,

SUB: OUTCOME OF THE BOARD MEETING

Ref: Regulation 30 and 33 of the SEBI (LODR) Regulation, 2015.

With reference to the above cited subject, we would like to inform you that the Board of Directors in the Meeting held today i.e. February 14, 2020 have approved the following:

- i. Standalone and Consolidated Unaudited Financial results for the third quarter and nine months ended December 31, 2019 along with Limited Review Report.
- ii. Appointment of Mr. Trupti Ranjan Mohanty (ACS 60358) as the Company Secretary of the Company in lieu of resignation of Mr. Pavan Pise.

In this regard, we are enclosing herewith a copy of the standalone and consolidated unaudited financial results along with Independent Auditor’s Limited Review report.

The meeting of the Board commenced at 12.15 pm and concluded at 4.25 pm. The results will be published in the newspaper in terms of Regulation 41(1)(b) of the SEBI (LODR) Regulation, 2015 in due course.

The above information will be made available on the Company’s website www.smslife.in.

Yours faithfully,

For SMS Lifesciences India Limited



N Rajendra Prasad
Authorised Signatory



SMS LIFESCIENCES INDIA LIMITED

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

Statement of Standalone Un-Audited Financial Results for the Quarter and 9 months Ended 31st December, 2019

(Rs. in Lakhs)

S.No	Particulars	Quarter Ended			9 Months Ended		Year ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	4,639.92	7,155.72	9,650.09	21,067.14	24,558.20	34,415.16
2	Other Income	30.17	80.44	12.94	138.04	88.50	252.87
3	Total Revenue	4,670.09	7,236.16	9,663.03	21,205.18	24,646.70	34,668.03
4	Expenses						
	(a) Cost of materials consumed	2,399.96	3,884.75	6,186.24	12,469.63	17,578.12	23,847.16
	(b) Changes in inventories	482.87	679.82	243.47	1,381.46	(1,665.92)	(818.57)
	(c) Manufacturing Expenses	737.85	902.70	1,226.68	2,740.59	3,609.71	4,777.39
	(d) Employee Benefits Expense	528.67	654.02	524.04	1,727.27	1,539.61	2,063.14
	(e) Finance costs	116.77	136.10	212.00	394.59	410.41	546.22
	(f) Depreciation and amortisation expense	179.23	179.91	151.00	534.98	428.79	576.98
	(g) Other expenses	226.99	255.55	327.11	739.98	903.55	1,299.88
	Total Expenses - (a to g)	4,672.34	6,692.85	8,870.54	19,988.51	22,804.27	32,292.20
5	Profit before Exceptional and Extraordinary Items and Tax (3-4)	(2.25)	543.31	792.50	1,216.67	1,842.43	2,375.83
6	Exceptional items	-	-	-	-	-	-
7	Profit before Extraordinary Items and Tax (5-6)	(2.25)	543.31	792.50	1,216.67	1,842.43	2,375.83
8	Extraordinary Items	-	-	-	-	-	-
9	Profit before Tax (7-8)	(2.25)	543.31	792.50	1,216.67	1,842.43	2,375.83
10	Tax Expenses						
	(1) Current Tax	-	170.00	240.00	370.00	550.00	630.00
	(2) Relating to Earlier years	-	-	-	-	-	(0.57)
	(3) Deferred Tax	26.41	23.90	42.17	79.06	33.89	83.07
11	Net Profit / (Loss) for the Period (9-10)	(28.66)	349.42	510.33	767.61	1,258.54	1,663.33
	Net Profit to Total Revenue	-0.62%	4.88%	5.29%	3.64%	5.12%	4.83%
12	Other Comprehensive Income/(Loss) (OCI):						
	(A) Items that will not be reclassified to statement of Profit & Loss						
	Remeasurements of post-employment benefit obligations	(2.66)	(2.44)	(3.07)	(7.31)	(8.26)	(8.86)
13	Total Other Comprehensive Income/(Loss) before related Tax	(2.66)	(2.44)	(3.07)	(7.31)	(8.26)	(8.86)
14	Income Tax on the above	(0.77)	(0.71)	(0.89)	(2.13)	(2.50)	(2.58)
15	Other Comprehensive Income/(Loss) after tax for the Year (13-14)	(1.88)	(1.73)	(2.18)	(5.18)	(5.76)	(6.28)
16	Total comprehensive Income for the period/year (11+15)	(30.54)	347.69	508.15	762.43	1,252.78	1,657.05
17	Earning Per Equity Share (of Rs.10/ each) (not annualised)						
	(a) Basic / Diluted	(0.95)	11.56	16.88	25.39	41.63	55.02
18	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
19	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						10,195.53



Notes:

- 1 The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 14th February, 2020 and have been approved by the Board of Directors at its meeting held on 14th February, 2020.
- 2 Results for the quarter ended 31st December, 2019 were subjected to 'Limited Review' by the Auditors and have expressed un modified audit opinion thereon.
- 3 The main reason for decrease in revenue during the current quarter as compared to previous quarter as well as corresponding period of previous year is due to worldwide issue of NDMA in respect of Rantidine Hcl and lack of clarity from Regulatory Authorities about its permissible level, its impact and about its carcinogenic effect on prolonged usage. However, with the USFDA notification which specifies the acceptable daily intake limit for NDMA. The product manufacturing by the company is well within the limits specified by the USFDA. Now the market is resuming gradually.
- 4 The above results are in accordance with the companies (Indian Accounting Standards) rules, 2015, (Ind AS) as ammended by Company (Ind AS) (ammendment) Rules, 2016, notified under Section 133 of the Companies Act 2013, read with relavent Rules issued there under and other accounting principals generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 5 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 6 The Ministry of Corporate Affairs (MCA), on 30th March, 2019 , notified Ind AS 116 "Leases" as part of the Companies (Indian Accounting Standard) Amendment Rules, 2019. The new Standard is effective for accounting periods beginning on or after 1st April, 2019. The adoption of the Standard did not have any material impact to the financial results of the Company.
- 7 Figures of previous period have been regrouped / rearranged wherever necessary.

Place: Hyderabad
Date : 14-02-2020

For SMS Lifesciences India Limited




TVVSN Murthy
Managing Director

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

Review Report to
The Board of Directors
SMS Lifesciences India Limited

We have reviewed the accompanying statement of unaudited standalone financial results of SMS Lifesciences India Limited ("the Company"), for the quarter and nine month period ended 31st December 2019 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements is free of material misstatement. A review of the interim financial information consists of making inquires primarily of companies personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified u/s 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 14-02-2020

For Rambabu & Co.,
Chartered Accountants
Reg. No.002976S



GVL Prasad
GVL Prasad
Partner
M. No. 026548

UDIN: 20026548AAAAAH977

SMS LIFESCIENCES INDIA LIMITED

(CIN: L74930TG2006PLC050223)

Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Statement of Consolidated Un-Audited Financial Results for the Quarter and 9 Months Ended 31st December, 2019

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			9 Months Ended		Year ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	4,659.26	7,636.26	10,307.20	21,479.58	27,062.92	37,785.22
2	Other Income	32.48	82.21	13.30	142.19	89.15	254.64
3	Total Revenue	4,691.74	7,718.47	10,320.49	21,621.77	27,152.06	38,039.86
4	Expenses						
	(a) Cost of materials consumed	2,291.03	3,470.62	6,950.66	11,654.83	19,930.09	26,879.44
	(b) Changes in inventories	455.02	1,184.86	(113.64)	1,975.66	(2,076.34)	(1,291.80)
	(c) Manufacturing Expenses	808.70	989.87	1,297.65	2,966.89	3,813.98	5,054.41
	(d) Employee Benefits Expense	602.40	766.09	603.61	1,981.68	1,704.27	2,311.08
	(e) Finance costs	117.29	139.41	212.05	398.57	414.56	550.68
	(f) Depreciation and amortisation expense	194.81	195.52	168.43	581.58	475.53	638.04
	(g) Other expenses	235.21	274.50	334.17	773.75	954.66	1,359.52
	Total Expenses - (a to h)	4,704.46	7,020.87	9,452.93	20,332.96	25,216.75	35,501.37
5	Profit before Exceptional and Extraordinary Items and Tax (3-4)	(12.72)	697.60	867.55	1,288.81	1,935.31	2,538.49
6	Exceptional items	-	-	-	-	-	-
7	Profit before Extraordinary Items and Tax (5-6)	(12.72)	697.60	867.55	1,288.81	1,935.31	2,538.49
8	Extraordinary Items	-	-	-	-	-	-
9	Profit Before Tax (7-8)	(12.72)	697.60	867.55	1,288.81	1,935.31	2,538.49
10	Tax Expenses						
	(1) Current Tax	-	201.00	258.00	410.00	574.00	670.00
	(2) Relating to Earlier years	-	-	-	-	0.78	(8.38)
	(3) Deferred Tax	21.20	20.58	42.17	68.67	33.89	92.15
11	Profit / (Loss) for the Period (9-10)	(33.92)	476.02	567.38	810.14	1,326.64	1,784.72
	Other Comprehensive Income/(Loss) (OCI):						
	Items that will not be reclassified to Statement of Profit/ (Loss)						
12	Remeasurements of post-employment benefit obligations	(1.06)	(1.01)	(3.07)	(3.00)	(8.26)	(3.69)
13	Total Other Comprehensive Income/(Loss) before related Tax	(1.06)	(1.01)	(3.07)	(3.00)	(8.26)	(3.69)
14	Income Tax effect on the above	(0.33)	(0.31)	(0.89)	(0.93)	(2.50)	(1.14)
15	Other Comprehensive Income/(Loss) after tax for the Period (13-14)	(0.73)	(0.70)	(2.18)	(2.07)	(5.76)	(2.55)
16	Total comprehensive Income for the period/year (11+15)	(34.65)	475.32	565.21	808.07	1,320.88	1,782.17
17	Earning Per Equity Share (of Rs.10/ each) (not annualised)						
	(a) Basic / Diluted	(1.12)	15.75	18.77	26.80	43.88	59.03
18	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
19	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						10,330.57





Notes:

- 1 The above consolidated Financial Results have been reviewed and recommended by the Audit Committee on 14th February, 2020 and have been approved by the Board
- 2 Results for the quarter ended 31st December, 2019 were subjected to 'Limited Review' by the Auditors and have expressed un modified audit opinion thereon.
- 3 The main reason for decrease in revenue during the current quarter as compared to previous quarter as well as corresponding period of previous year is due to worldwide issue of NDMA in respect of Rantidine Hcl and lack of clarity from Regulatory Authorities about its permissible level, its impact and about its carcinogenic effect on prolonged usage. However, with the USFDA notification which specifies the acceptable daily intake limit for NDMA. The product manufacturing by the company is well within the limits specified by the USFDA. Now the market is resuming gradually.
- 4 The consolidated financial results of the Group have been prepared in accordance with the companies (Indian Accounting Standards) rules, 2015, (Ind AS) as ammended by Company (Ind AS) (ammendement) Rules, 2016, notified under Section 133 of the Companies Act 2013, read with relavent Rules issued there under and other accounting principals generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 5 The consolidated financial results for the quarter and nine month ended 31st December, 2019 includes financial resu1ts of its Whollyolly owned Subsidiary, Mahi Drugs Private Limited.
- 6 The Group is engaged in the manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 7 The Ministry of Corporate Affairs (MCA), on 30th March, 2019 , notified Ind AS 116 "Leases" as part of the Companies (Indian Accounting Standard) Amendment Rules, 2019. The new Standard is effective for accounting periods beginning on or after 1st April, 2019. The adoption of the Standard did not have any material impact to the financial results of the Group.
- 8 Figures of previous period have been regrouped / rearranged wherever necessary.

Place: Hyderabad
Date : 14-02-2020

For **SMS Lifesciences India Limited**




TVVSN Murthy
Managing Director

Limited Review Report

To the Board of Directors
SMS Lifesciences India Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of SMS Lifesciences India Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31st December, 2019 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following subsidiary:

a. Mahi Drugs Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad

Date: 14-02-2020

For Rambabu & Co.,

Chartered Accountants

Reg. No.002976S



GVL Prasad

Partner

M. No. 026548

UDIN: 20026548AAAAAI7432